- Patents valid through 2038
- Clinical topline results
from Phase 2b ALS trial expected in
H2 2023
CAMBRIDGE, Mass., Sept. 19,
2023 /PRNewswire/ -- NeuroSense Therapeutics
Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments
for severe neurodegenerative diseases, today announced that the
European, Japan, and Israel Patent
Offices have granted the Company a key patent relating to
"Compositions comprising an anti-inflammatory drug and a dicer
activator for use in treatment of neuronal diseases." The patents
relate to NeuroSense's unique fixed-dose combination of
ciprofloxacin and celecoxib, two U.S. Food and Drug Administration
(FDA) approved drugs that are the active ingredients in PrimeC, the
Company's lead drug candidate for treating Amyotrophic Lateral
Sclerosis (ALS).
Corresponding patents have been issued in the U.S., Canada, and Australia and are valid through 2038, subject
to appropriate maintenance. Additional patent applications relating
to the novel formulation of PrimeC and methods for the
treatment of other neurodegenerative diseases using NeuroSense's
platform of combination therapies including StabiliC and CogniC are
pending as well.
"We are pleased to receive this most recent patent grant in
Europe, Japan, and Israel, which adds to our growing IP estate as
we expect the clinical read-out from our PARADIGM Phase
2b study towards year's end. ALS
remains a pressing unmet need, and our unwavering commitment to
advancing our program, supported by robust intellectual property,
underscores our dedication to delivering an effective therapy for
individuals battling ALS." stated Alon
Ben-Noon, NeuroSense's CEO.
About NeuroSense
NeuroSense Therapeutics, Ltd. is a clinical-stage biotechnology
company focused on discovering and developing treatments for
patients suffering from debilitating neurodegenerative diseases.
NeuroSense believes that these diseases, which include amyotrophic
lateral sclerosis (ALS), Alzheimer's disease and Parkinson's
disease, among others, represent one of the most significant unmet
medical needs of our time, with limited effective therapeutic
options available for patients to date. Due to the complexity of
neurodegenerative diseases and based on strong scientific research
on a large panel of related biomarkers, NeuroSense's strategy is to
develop combined therapies targeting multiple pathways associated
with these diseases.
For additional information, we invite you to visit
our website and follow us
on LinkedIn and Twitter.
Forward-Looking Statements
This press release contains "forward-looking statements" that
are subject to substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. Forward-looking statements
contained in this press release may be identified by the use of
words such as "anticipate," "believe," "contemplate," "could,"
"estimate," "expect," "intend," "seek," "may," "might," "plan,"
"potential," "predict," "project," "target," "aim," "should,"
"will" "would," or the negative of these words or other similar
expressions, although not all forward-looking statements contain
these words. Forward-looking statements are based on NeuroSense
Therapeutics' current expectations and are subject to inherent
uncertainties, risks and assumptions that are difficult to predict
and include statements regarding the timing of top-line results of,
and the results of, the PARADIGM clinical trial. Further,
forward-looking statements are subject to a number of risks and
uncertainties as a result of which actual results could differ
materially and adversely from those anticipated or implied in the
forward looking statements. These risks include a delay in the
reporting of top-line results from PARADIGM clinical trial; greater
than anticipated costs and expenses; the potential for PrimeC to
safely and effectively target ALS; preclinical and clinical data
for PrimeC; the timing of current and future clinical trials,
timing for reporting data; the nature, strategy and focus of the
company and further updates with respect thereto; the development
and commercial potential of any product candidates of the company;
and other risks and uncertainties set forth in NeuroSense's filings
with the Securities and Exchange Commission (SEC), including
NeuroSense's Annual Report on Form 20-F filed with the SEC on
March 22, 2023. Forward-looking
statements contained in this announcement are made as of this date,
and NeuroSense Therapeutics Ltd. undertakes no duty to update such
information except as required under applicable law.
Logo -
https://mma.prnewswire.com/media/1707291/NeuroSense_Therapeutics_Logo.jpg
View original
content:https://www.prnewswire.com/news-releases/neurosense-granted-patents-in-europe-japan-and-israel-for-its-als-drug-primec-301931701.html
SOURCE NeuroSense
